BNT162b2

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

SARS-CoV-2 Infection, COVID19

Conditions

SARS-CoV-2 Infection, COVID19

Trial Timeline

Oct 15, 2021 → Jul 23, 2023

NCT ID

NCT04895982

About BNT162b2

BNT162b2 is a phase 2 stage product being developed by Pfizer for SARS-CoV-2 Infection, COVID19. The current trial status is completed. This product is registered under clinical trial identifier NCT04895982. Target conditions include SARS-CoV-2 Infection, COVID19.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2 Infection, COVID19 were approved

Approved (4) Terminated (1) Active (16)

✅mRNA-1273 Variant-containing FormulationModernaApproved

✅mRNA-1273ModernaApproved

✅AZD1222AstraZenecaApproved

✅BNT162b2PfizerApproved

🔄mRNA-1273ModernaPhase 3

🔄mRNA-1083ModernaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06923137	Pre-clinical	Active	Apr 16, 2025	Oct 31, 2030	COVID-19 SARS-CoV-2 Infection
NCT05621239	Pre-clinical	Completed	Mar 15, 2023	Apr 3, 2023	COVID-19
NCT04895982	Phase 2	Completed	Oct 15, 2021	Jul 23, 2023	SARS-CoV-2 Infection, COVID19
NCT04880447	Pre-clinical	Completed	May 26, 2021	Apr 14, 2022	COVID-19
NCT04816669	Phase 3	Completed	Apr 1, 2021	Dec 2, 2021	SARS-CoV-2 Infection
NCT04815031	Pre-clinical	Completed	Mar 20, 2021	Jan 27, 2023	COVID-19
NCT04754594	Phase 2/3	Completed	Feb 16, 2021	Jul 15, 2022	SARS-CoV-2 Infection
NCT04588480	Approved	Completed	Oct 21, 2020	Nov 25, 2021	SARS-CoV-2 Infection

Competing Products

20 competing products in SARS-CoV-2 Infection, COVID19

See all competitors

Product	Company	Stage
mRNA-1010	Moderna	Phase 1
mRNA-1273	Moderna	Preclinical
mRNA-1273	Moderna	Phase 1
mRNA-1283	Moderna	Phase 1
mRNA-1273	Moderna	Preclinical
mRNA-1083 Composition 1 Dose A Lot A	Moderna	Phase 2
mRNA-1273.214	Moderna	Phase 2
SPIKEVAX	Moderna	Preclinical
mRNA-1273	Moderna	Phase 3
mRNA-1273	Moderna	Phase 3
mRNA-1273	Moderna	Preclinical
mRNA-1083.1	Moderna	Phase 2
SPIKEVAX Bivalent	Moderna	Preclinical
mRNA-1083	Moderna	Phase 3
mRNA-1273	Moderna	Phase 2
mRNA-1073	Moderna	Phase 2
mRNA-1273	Moderna	Phase 3
mRNA-1273	Moderna	Preclinical
mRNA-1273.211	Moderna	Phase 3
SPIKEVAX (mRNA-1273)	Moderna	Preclinical